UEMS Medical Specialty
Metabolic & Endocrinology
Nutraceutical approaches to metabolic dysregulation: GLP-1 companion formulas, insulin sensitisers, thyroid support, adipokine modulation, and comprehensive metabolic syndrome management.
26
dossiers
Post-GLP-1 Metabolic Optimization
Evidence-Based Dietary Patterns, Ultra-Processed Foods, and Sodium-Potassium Balance: 2025-2026 Insights
Translating nuanced dietary evidence regarding food processing, quality, and electrolyte balance into convenient, effective, and compliant nutritional products for specific patient populations is a complex CDMO challenge. Ensuring palatability and long-term adherence to these precise formulations adds further difficulty.
Glycolysis-Restricted FSMP (Oncology Nutrition)
Medical Foods and Foods for Special Medical Purposes: Regulatory Frameworks and Clinical Nutrition Across Key Regions
Navigating the complex and divergent regulatory frameworks for medical foods in the US and FSMPs in the EU/GCC makes consistent product development, labelling, and market access a significant hurdle for specialized clinical nutrition.
Microvascular Hemodynamics & Endothelial Integrity
Erythritol and Human Health, 2020–2026: A PRISMA-Style Systematic Evidence Synthesis
Formulators face the critical challenge of ensuring product safety and consumer trust when using erythritol, given emerging data on its acute cardiovascular effects and potential long-term risks, especially at high intake levels common in ketogenic or diabetic products.
Intracellular Defense & IV-Alternatives
Integrated Metabolic Pathways for Immune Support, Fatigue Reduction, and Cellular Protection: A Mechanistic Review
Designing effective nutritional or pharmaco-nutritional interventions is challenging given the complex, interconnected nature of metabolic pathways supporting immunity, energy, and cellular protection. Delivering pleiotropic compounds efficiently to multiple intracellular targets without systemic burden is critical.
Glycolysis-Restricted FSMP (Oncology Nutrition)
The Glucose Paradox in Oncology Nutrition: High-Glycemic Medical Foods and Cancer Outcomes
Current sugar-dominant oncology medical foods may inadvertently fuel tumor growth and worsen metabolic dysfunction in cancer patients. Developing nutritionally complete, low-glycemic formulations that support anabolism without pro-oncogenic effects is a critical challenge.
Female Endocrine-Metabolic Crosstalk
Intrapartum Bioenergetics: Rheological Engineering of a Carbohydrate-Based Hydrogel Matrix to Overcome Delayed Gastric Emptying During Active Labour
Developing a carbohydrate-based oral formulation for active labour presents a challenge: it must rapidly deliver energy and prevent neonatal hypoglycemia without exacerbating delayed gastric emptying, increasing aspiration risk, or inducing maternal/neonatal hyperglycemia.
Cerebral Bioenergetics & Neuro-Metabolic Rescue
Ketogenic Interventions in Neurodegeneration: Mechanisms, Clinical Efficacy, and Therapeutic Challenges
Developing clinically robust and compliant ketogenic interventions for neurodegenerative diseases requires overcoming challenges related to variable metabolic responses, sustained therapeutic ketosis, and precise delivery of ketone bodies or precursors in diverse patient populations.
Cerebral Bioenergetics & Neuro-Metabolic Rescue
Contemporary Sleep Disorder Management: ICSD-3-TR Diagnostic & Therapeutic Insights
Formulating effective, mechanism-directed therapeutics for the diverse and often comorbid sleep disorder endotypes is challenging due to complex pathophysiology, diagnostic delays, and the need for precision targeting based on individual biomarkers.
Female Endocrine-Metabolic Crosstalk
Neuroendocrine, Metabolic, and Inflammatory Mechanisms in Polycystic Ovary Syndrome Pathogenesis
PCOS pathophysiology involves complex, self-reinforcing loops of neuroendocrine dysfunction, hyperandrogenism, and metabolic dysregulation, making targeted therapeutic delivery and efficacy challenging for multi-modal interventions.
Cellular Longevity & Senolytics
Clock Gene Expression (CLOCK/BMAL1) Impact on Pharmacokinetics: Implications for Chrononutrition and Chronopharmacology
Current pharmaceutical and nutritional guidelines often neglect circadian rhythmicity, leading to suboptimal therapeutic efficacy and unpredictable pharmacokinetic profiles for molecular interventions. Integrating clock gene biology into dosing regimens requires precise understanding of ADME variations.
Post-GLP-1 Metabolic Optimization
Drug-Induced Nutrient Depletion (DIND): Molecular Mechanisms of Iatrogenic Deficiencies in Chronic Pharmacotherapy
Mitigating drug-induced nutrient depletion requires advanced CDMO solutions to formulate targeted nutritional support that is compatible with existing chronic pharmacotherapy and addresses diverse mechanistic pathways of depletion.
Microvascular Hemodynamics & Endothelial Integrity
Modulation of the Endothelial Glycocalyx and Vitamin K2-Dependent MGP Carboxylation in the Prevention of Vascular Calcification
Developing bioavailable formulations of vitamin K2 (MK-7) and novel compounds to robustly enhance endothelial glycocalyx integrity and MGP carboxylation for the prevention or reversal of vascular calcification presents significant delivery and stability challenges.
Female Endocrine-Metabolic Crosstalk
Female Endocrine-Metabolic Axis: Formulation Technologies for Inositols and Antioxidants
Formulating stable, bioavailable, and patient-compliant products with precise inositol isomer ratios and sensitive antioxidants for female endocrine-metabolic health presents challenges in ingredient stability, dissolution, and avoiding paradoxical clinical effects from incorrect dosages.
Post-GLP-1 Metabolic Optimization
Amino-Peptide Matrices for Lean Mass Preservation in GLP-1 Receptor Agonist-Induced Gastroparesis
GLP-1 RA-induced gastroparesis and retained gastric contents present a significant challenge for effective oral nutrition delivery and lean mass preservation during weight loss therapy, especially in at-risk populations.
Cellular Longevity & Senolytics
Immunometabolism, Active Resolution of Inflammation, and Specialized Pro-resolving Mediators (SPMs) from EPA/DHA
Current anti-inflammatory strategies often inhibit active resolution pathways, leading to chronic inflammation. Developing stable, bioavailable specialized pro-resolving mediators (SPMs) or modulators that enhance endogenous SPM biosynthesis without compromising resolution is a significant challenge.
Post-GLP-1 Metabolic Optimization
In Vivo Gene Editing via Lipid Nanoparticles: Base Editor Mechanisms and PCSK9 Targeting
Developing safe, durable, and highly targeted in vivo delivery systems for gene editing machinery (e.g., mRNA encoding base editors) to specific tissues like the liver via LNPs remains a significant challenge, requiring precise control over biodistribution and off-target effects.
Cellular Longevity & Senolytics
Targeted Mitochondrial Medicine: Synergistic Modulation of AMPK and NAD⁺ Salvage Pathways for Cardiometabolic Health
The challenge lies in developing stable, bioavailable, and synergistically effective combination formulations of NAD⁺ precursors and AMPK modulators to precisely target cellular bioenergetic decline in age-related cardiometabolic conditions.
Post-GLP-1 Metabolic Optimization
Nutraceutical Toxicology and Herb-Drug Interactions (HDI/NDI): A Clinical Review of Six Critical Pharmacological Mechanisms
Developing safe and effective drug formulations requires comprehensive consideration of potential, often undisclosed, herb-drug interactions that can compromise efficacy or lead to life-threatening toxicities, especially with narrow therapeutic index compounds.
Precision Microbiome & Gut-Brain Axis
Pharmacomicrobiomics: Gut Microbiota Modulation of Drug Efficacy and Nutraceutical Biotransformation
Integrating the profound and variable metabolic capacity of the gut microbiome into pharmaceutical development to ensure consistent drug efficacy and bioavailability across diverse patient populations is a significant hurdle.
Post-GLP-1 Metabolic Optimization
Triple Agonists and Next-Generation Oral GLP-1s: Advancements in Metabolic Disorder Therapeutics
Formulating complex multi-receptor agonists and high-potency oral GLP-1 peptides requires advanced delivery systems to ensure bioavailability, stability, and patient adherence while mitigating gastrointestinal side effects.
Catecholamine Homeostasis & Executive Function
Clinical Nutrigenomics: One-Carbon Metabolism, MTHFR/COMT Polymorphisms, and Unmetabolized Folic Acid Toxicity
Developing stable, bioavailable dosage forms of 5-methyltetrahydrofolate (5-MTHF) that effectively bypass common one-carbon metabolism genetic polymorphisms (e.g., MTHFR, COMT) is critical to prevent unmetabolized folic acid (UMFA) toxicity and ensure optimal folate status. This requires precise formulation to overcome stability issues inherent to reduced folates while ensuring clinical efficacy across genetically diverse populations.
Female Endocrine-Metabolic Crosstalk
Household Xenoestrogens and Nutritional Interventions: A Translational Endocrine Defense Framework
Designing medical foods that mitigate the effects of chronic, low-dose exposure to diverse endocrine-disrupting chemical mixtures, while adhering to regulatory definitions and ensuring compatibility with polypharmacy risks.
Intracellular Defense & IV-Alternatives
Isomeric Stabilization in High-Moisture Matrices: Protecting Fixed-Ratio Inositol Formulations
Fixed-ratio solid formulations are prone to segregation during manufacturing, especially under moisture-driven property changes, causing dose uniformity and accuracy challenges.
Cerebral Bioenergetics & Neuro-Metabolic Rescue
Ketogenic Diet-Specified Interventions in Neurodegenerative Disease Mechanisms
Developing a formulation that achieves consistent and measurable ketosis while optimizing bioavailability and tolerability in neurodegenerative conditions is a key challenge.
No dossiers match the selected MeSH topic in this page. Try another tag or clear the filter.
Custom Formulation Available
Need a Dossier Built Around Your Molecule?
Our R&D team will conduct a Paid Discovery Audit and build a proprietary clinical dossier for your specific active ingredient or therapeutic target. Full IP transfer included.